Urethral sphincteric insufficiency in postmenopausal females: treatment with phenylpropanolamine and estriol separately and in combination. A urodynamic and clinical evaluation
- PMID: 6541387
- DOI: 10.1159/000280978
Urethral sphincteric insufficiency in postmenopausal females: treatment with phenylpropanolamine and estriol separately and in combination. A urodynamic and clinical evaluation
Abstract
A randomized open comparative cross-over trial was carried out in 20 postmenopausal women, mean age 69 years, suffering from urinary incontinence due to urethral sphincteric insufficiency. They were treated with phenylpropanolamine (PPA) 50 mg p.o. twice daily or estriol vaginal suppositories 1 mg daily separately and in combination for periods of 4 weeks. Urodynamic investigations were carried out before and after each period of treatment. Both PPA and estriol increased the maximal urethral closure pressure and the continence area significantly compared to the initial values, but combined treatment was substantially more effective. The functional urethral length increased significantly while on estriol. No significant change was registered in the bladder pressure or in the pressure transmission ratio. PPA was clinically more effective than estriol, but not sufficient to obtain complete continence. With combined treatment 8 patients became completely continent, 9 were considerably improved and only 1 patient remained unchanged. 2 patients dropped out of the study because of side effects. Combined treatment with PPA and estriol represents a recommendable treatment to postmenopausal women with urinary incontinence due to urethral sphincteric insufficiency.
Similar articles
-
Effect of combined treatment with phenylpropanolamine and estriol, compared with estriol treatment alone, in postmenopausal women with stress urinary incontinence.Gynecol Obstet Invest. 1990;30(1):37-43. doi: 10.1159/000293211. Gynecol Obstet Invest. 1990. PMID: 2227611 Clinical Trial.
-
Estrogens and phenylpropanolamine in combination for stress urinary incontinence in postmenopausal women.Urology. 1988 Sep;32(3):273-80. doi: 10.1016/0090-4295(88)90400-1. Urology. 1988. PMID: 3046105 Clinical Trial.
-
Stress incontinence in females: treatment with phenylpropanolamine. A urodynamic and pharmacological evaluation.Urol Int. 1983;38(5):293-9. doi: 10.1159/000280909. Urol Int. 1983. PMID: 6685364
-
[Urinary incontinence in castrated female dogs. 2. Therapy].Tierarztl Prax. 1995 Aug;23(4):402-6. Tierarztl Prax. 1995. PMID: 8578574 Review. German.
-
Medical therapy for acquired urinary incontinence in dogs.Int J Pharm Compd. 2012 Sep-Oct;16(5):369-75. Int J Pharm Compd. 2012. PMID: 23072196 Review.
Cited by
-
Expression of α1 receptor and nitric oxide synthase in oophorectomized and estrogen-supplemented rat bladder and urethra.Korean J Urol. 2014 Oct;55(10):677-86. doi: 10.4111/kju.2014.55.10.677. Epub 2014 Oct 10. Korean J Urol. 2014. PMID: 25324952 Free PMC article.
-
Postmenopausal hormone therapy: does it cause incontinence?Obstet Gynecol. 2005 Nov;106(5 Pt 1):940-5. doi: 10.1097/01.AOG.0000180394.08406.15. Obstet Gynecol. 2005. PMID: 16260510 Free PMC article. Clinical Trial.
-
Local Oestrogen for Pelvic Floor Disorders: A Systematic Review.PLoS One. 2015 Sep 18;10(9):e0136265. doi: 10.1371/journal.pone.0136265. eCollection 2015. PLoS One. 2015. PMID: 26383760 Free PMC article.
-
Comparative studies on urethral function.World J Urol. 1996;14(6):388-92. doi: 10.1007/BF00183121. World J Urol. 1996. PMID: 8986042
-
Estrogen therapy and urinary incontinence: what is the evidence and what do we tell our patients?Int Urogynecol J Pelvic Floor Dysfunct. 2006 Sep;17(5):541-5. doi: 10.1007/s00192-006-0080-3. Epub 2006 Mar 15. Int Urogynecol J Pelvic Floor Dysfunct. 2006. PMID: 16538421 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical